Targeted Therapies for Hepatocellular Carcinoma
TLDR
Identification of oncogenes that mediate tumor progression, and trials that monitor their products as biomarkers, might lead to personalized therapy; reagents that interfere with signaling pathways required for HCC progression might be used to treat selected populations, and thereby maximize the efficacy and cost benefit.About:
This article is published in Gastroenterology.The article was published on 2011-05-01 and is currently open access. It has received 402 citations till now. The article focuses on the topics: Sorafenib & Targeted therapy.read more
Citations
More filters
Journal ArticleDOI
FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity
TL;DR: It is suggested that FTY720 sensitizes HCC cells to cytotoxic effects induced by treatment with sorafenib alone, and warrants further investigations of combined treatment with SorafenIB and F TY720 in vivo in order to develop more effective treatment of HCC.
Journal ArticleDOI
Janus nanocarriers for magnetically targeted and hyperthermia-enhanced curcumin therapy of liver cancer
Hao Xing,Hao Xing,Zheng Wang,Zheng Wang,Dan Shao,Zhimin Chang,Mingfeng Ge,Li Li,Mingdi Wu,Zhuangzhi Yan,Wen-Fei Dong +10 more
TL;DR: Results demonstrated that Janus M-MSNs-Cur possessed a high therapeutic efficiency and excellent biosafety both in vitro and in vivo, indicating that it might be a promising therapeutic agent for liver cancer treatment.
Journal ArticleDOI
Potential Molecular Targets of Statins in the Prevention of Hepatocarcinogenesis.
Ezequiel Ridruejo,Giselle Romero-Caími,María Jesús Obregón,Diana Kleiman de Pisarev,Laura Alvarez +4 more
TL;DR: In this article, the effects of different doses of Atorvastatin (AT) and Simvastat (SM) on HCC induced proliferation and analyzed proliferative parameters, cholesterol metabolism, TGF-βΙ mRNA, c-Src and thyroid hormones (TH) levels.
Journal ArticleDOI
Astrocyte elevated gene-1 overexpression in hepatocellular carcinoma: an independent prognostic factor
Hae Il Jung,Taesung Ahn,Sang Ho Bae,Jun Chul Chung,Hyungjoo Kim,Susie Chin,Dongjun Jeong,Hyon Doek Cho,Moon Soo Lee,Hyung Chul Kim,Chang Ho Kim,Moo-Jun Baek +11 more
TL;DR: It is suggested that AEG-1 overexpression could serve as a valuable prognostic marker in patients with HCC.
Journal Article
Promoter methylation assay of SASH1 gene in breast cancer
Lin Sheyu,Liu Hui,Zhang Junyu,Xu Jiawei,Wang Honglian,Sang Qing,Zhang Hengwei,Guo Xuhui,Xing Qinghe,He Lin +9 more
TL;DR: It is proposed that increase of DNA methylation level in the promoter region of gene SASH1, particularly CpG_26.27 or C pG_54.55 sites, possibly repressed Sash1 expression in breast cancer.
References
More filters
Journal ArticleDOI
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Journal ArticleDOI
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Journal ArticleDOI
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more
TL;DR: Results suggest that EGFR mutations may predict sensitivity to gefitinib, and treatment with the EGFR kinase inhibitor gefitsinib causes tumor regression in some patients with NSCLC, more frequently in Japan.
Journal ArticleDOI
Cancer Statistics, 2009
TL;DR: The most recent data on cancer incidence, mortality, and survival from the American Cancer Society (ACS) is presented in this paper, where the authors compare the three major cancer sites in men (lung, prostate, and colon and rectum [colorectum]) and in two major cancers sites in women (breast and colorectal) over a 15-year period.
Journal ArticleDOI
Management of hepatocellular carcinoma: An update
Jordi Bruix,Morris Sherman +1 more
TL;DR: The American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) were updated in 2010 as discussed by the authors.
Related Papers (5)
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more